SU9516: biochemical analysis of cdk inhibition and crystal structure in complex with cdk2

被引:47
作者
Moshinsky, DJ
Bellamacina, CR
Boisvert, DC
Huang, P
Hui, T
Jancarik, J
Kim, SH
Rice, AG
机构
[1] SUGEN Inc, San Francisco, CA 94080 USA
[2] Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA
关键词
cdk2; crystal structure; kinase; inhibitor; SU9516;
D O I
10.1016/j.bbrc.2003.09.114
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
SU9516 is a 3-substituted indolinone compound with demonstrated potent and selective inhibition toward cyclin dependent kinases (cdks). Here, we describe the kinetic characterization of this inhibition with respect to cdk2, 1, and 4, along with the crystal structure in complex with cdk2. The molecule is competitive with respect to ATP for cdk2/cyclin A, with a K-i value of 0.031 muM. Similarly, SU9516 inhibits cdk2/cyclin E and cdk1/cyclin 131 in an ATP-competitive manner, although at a 2- to 8-fold reduced potency. In contrast, the compound exhibited non-competitive inhibition with respect to ATP toward cdk4/cyclin D I, with a 45-fold reduced potency. The X-ray crystal structure of SU9516 bound to cdk2 revealed interactions between the molecule and Leu83 and Glu81 of the kinase. This study should aid in the development of more potent and selective cdk inhibitors for potential therapeutic agents. (C) 2003 Elsevier Inc. All rights reserved.
引用
收藏
页码:1026 / 1031
页数:6
相关论文
共 33 条
  • [11] Lane ME, 2001, CANCER RES, V61, P6170
  • [12] Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2
    Lawrie, AM
    Noble, MEM
    Tunnah, P
    Brown, NR
    Johnson, LN
    Endicott, JA
    [J]. NATURE STRUCTURAL BIOLOGY, 1997, 4 (10) : 796 - 801
  • [13] McMahon G, 2000, Oncologist, V5 Suppl 1, P3
  • [14] Mendel DB, 2000, ANTI-CANCER DRUG DES, V15, P29
  • [15] Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects
    Mettey, Y
    Gompel, M
    Thomas, V
    Garnier, M
    Leost, M
    Ceballos-Picot, I
    Noble, M
    Endicott, J
    Vierfond, JM
    Meijer, L
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (02) : 222 - 236
  • [16] Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors
    Mohammadi, M
    McMahon, G
    Sun, L
    Tang, C
    Hirth, P
    Yeh, BK
    Hubbard, SR
    Schlessinger, J
    [J]. SCIENCE, 1997, 276 (5314) : 955 - 960
  • [17] Cyclin-dependent kinases: Engines, clocks, and microprocessors
    Morgan, DO
    [J]. ANNUAL REVIEW OF CELL AND DEVELOPMENTAL BIOLOGY, 1997, 13 : 261 - 291
  • [18] CYCLIN-DEPENDENT PROTEIN-KINASES - KEY REGULATORS OF THE EUKARYOTIC CELL-CYCLE
    NIGG, EA
    [J]. BIOESSAYS, 1995, 17 (06) : 471 - 480
  • [19] OLASHAW N, 2002, SCI STKE, pRE7
  • [20] Pyrazolo[3,4-b]quinoxalines.: A new class of cyclin-dependent kinases inhibitors
    Ortega, MA
    Montoya, ME
    Zarranz, B
    Jaso, A
    Aldana, I
    Leclerc, S
    Meijer, L
    Monge, A
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY, 2002, 10 (07) : 2177 - 2184